SPECT/CT for medication-related osteonecrosis of the jaw with bone metastases of cancer: Maximum standardized uptake values comparison between jaw lesions and bone metastases

Document Type : Original Article

Authors

1 Quantitative Diagnostic Imaging, Field of Oral and Maxillofacial Imaging and Histopathological Diagnostics, Course of Applied Science, The Nippon Dental University Graduate School of Life Dentistry at Niigata, Niigata, Japan

2 Department of Oral and Maxillofacial Radiology, The Nippon Dental University School of Life Dentistry at Niigata, Niigata, Japan

Abstract

Introduction: Medication-related osteonecrosis of the jaw (MRONJ) is a complication of medication for bone metastases patients. This study aimed to examine SPECT/CT for MRONJ with bone metastases of cancer, especially maximum standardized uptake values (SUVmax) comparison between the jaw lesions and bone metastases.
Methods: Thirty-one MRONJ patients with bone metastases of cancer underwent bone SPECT/CT, and the SUVmax were obtained with a workstation. The SUVmax of jaw lesions of MRONJ and bone metastases of cancer were compared in staging of MRONJ, location of MRONJ, primary cancer, location of bone metastases and medication for bone metastases.
Results: The SUVmax of bone metastases of cancer (33.3±27.2) were significantly higher than those of jaw lesions of MRONJ (17.6±10.0, p = 0.001). Furthermore, the SUVmax for stage 2, mandible, prostate cancer, vertebra and zoledronate were significantly different between the jaw lesions of MRONJ and bone metastases of cancer.
Conclusion: This study indicated the SUVmax with SPECT/CT was different between the jaw lesions and bone metastases, and the data could be effective for the management in MRONJ patients with bone metastases.

Keywords

Main Subjects

References

  1. Lee CH, Son SH, Hong CM, Jeong JH, Jeong SY, Lee SW, Lee J, Kwon TG, Ahn BC. Prevalence and risk factors of atypical femoral fracture bone scintigraphic feature in patients experiencing bisphosphonate-related osteonecrosis of the jaw. Nucl Med Mol Imaging. 2018;52:311-7.
  2. Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons’ position paper on medication-related osteonecrosis of the jaws-2022 update. J Oral Maxillofac Surg. 2022;80:920-43.
  3. Ogura I, Sasaki Y, Sue M, Oda T, Kameta A, Hayama K. Tc-99m hydroxymethylene diphosphonate scintigraphy, computed tomography, and magnetic resonance imaging of osteonecrosis in the mandible: osteoradionecrosis versus medication-related osteonecrosis of the jaw. Imaging Sci Dent. 2019;49:53-8.
  4. Ogura I, Sasaki Y, Sue M, Oda T, Kameta A, Hayama K. Tc-99m hydroxymethylene diphosphonate SPECT/CT for the evaluation of osteonecrosis of the jaw: preliminary study on diagnostic ability of maximum standardised uptake value. Clin Radiol. 2020;75:46-50.
  5. Ogura I, Kobayashi E, Nakahara K, Igarashi K, Haga-Tsujimura M, Toshima H. Quantitative SPECT/CT imaging for medication-related osteonecrosis of the jaw: a preliminary study using volume-based parameters, comparison with chronic osteomyelitis. Ann Nucl Med. 2019;33:776-82.
  6. Toshima H, Ogura I. Assessment of inflammatory jaw pathologies using bone SPECT/CT maximum standardized uptake value. Dentomaxillofac Radiol. 2020;49:20200043.
  7. Minami Y, Ogura I. Bone single-photon emission computed tomography-CT peak standardized uptake value for chronic osteomyelitis, osteoradionecrosis and medication-related osteonecrosis of the jaw. J Med Imaging Radiat Oncol. 2021;65:160-5.
  8. Ogawa R, Ogura I. Analysis of medication-related osteonecrosis of the jaw with bone SPECT/CT: relationship between patient characteristics and maximum standardized uptake value. Dentomaxillofac Radiol. 2021;50:20200516.
  9. Minami Y, Ogura I. Comparison of maximum and mean standardized uptake values of jaw pathologies with bone SPECT/CT: an especial focus on medication-related osteonecrosis of the jaw. Nucl Med Commun. 2022;43:1188-94.
  10. Minami Y, Ogawa R, Ogura I. Volumetric analysis of mandibular lesions with SPECT/CT: a pilot clinical study of maximum standardized uptake value. Pol J Radiol. 2022;87:e311-5.
  11. Tezuka Y, Ogura I. Maximum and mean standardized uptake values of medication-related osteonecrosis of the jaw with bone SPECT/CT: comparison of mandibular pathologies, control and temporomandibular joints. Dentomaxillofac Radiol. 2023;52:20230119.
  12. Shirai A, Ogura I. Evaluation of jaw pathologies of patients with medication-related osteonecrosis of the jaw using a computer program to assess the bone scan index: comparison of standardized uptake values with bone SPECT/CT. Nucl Med Commun. 2024;45:1007-12.
  13. Kuji I, Yamane T, Seto A, Yasumizu Y, Shirotake S, Oyama M. Skeletal standardized uptake values obtained by quantitative SPECT/CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer. Eur J Hybrid Imaging. 2017;1:2.
  14. Tabotta F, Jreige M, Schaefer N, Becce F, Prior JO, Nicod Lalonde M. Quantitative bone SPECT/CT: high specificity for identification of prostate cancer bone metastases. BMC Musculoskelet Disord. 2019;20:619.
  15. Mohd Rohani MF, Mat Nawi N, Shamim SE, Wan Sohaimi WF, Wan Zainon WMN, Musarudin M, Said MA, Hashim H. Maximum standardized uptake value from quantitative bone single-photon emission computed tomography/computed tomography in differentiating metastatic and degenerative joint disease of the spine in prostate cancer patients. Ann Nucl Med. 2020;34:39-48.
  16. Zhang Y, Li B, Yu H, Song J, Zhou Y, Shi H. The value of skeletal standardized uptake values obtained by quantitative single-photon emission computed tomography-computed tomography in differential diagnosis of bone metastases. Nucl Med Commun. 2021;42:63-7.
  17. Tezuka Y, Ogura I. Maximum standardized uptake value of normal structures in the head and neck with bone SPECT/CT. J Med Imaging Radiat Oncol. 2022;66:936-9.

Files

Share

How to cite

Statistics